On March 18, 2022, the FDA approved the combination of relatlimab (anti-LAG3) and nivolumab (anti-PD-1) for unresectable or metastatic melanoma, marking LAG3 as the third validated immune checkpoint target after CTLA-4 and PD-1 (18). Here, PDCD1 is linked to metastatic melanoma.